NEWS AND ANNOUNCEMENTS

Ed Richman is interviewed by Mixergy.com
Lower Gwynedd, PA – April 1, 2010 –

Mixergy.com is a video blog focused on interviewing entrepreneurs. Ed Richman's interview on Mixergy.com.

Ed Richman is interviewed on WWDB 860AM
Philadelphia, PA -

Ed Richman was interviewed by Herb Cohen on Executive Leadership

Richman Chemical Inc. Supplies Acetonitrile, HPLC Grade
Lower Gwynedd, PA – May 20, 2009 – Richman Chemical Inc. (RCI) is filling a huge gap in the specialty chemicals marketplace by offering acetonitrile, HPLC grade.  At a time when reliable acetonitrile supplies are dwindling as a result of sluggish demand for acrylonitrile, RCI has coordinated an effort to offer HPLC-grade solvent produced via a novel purification route. Specifically, the product exhibits the key ultraviolet absorbance characteristics consistent with HPLC-grade compliance (Chart 1).  This new product offering is strategically advantageous for pharmaceutical companies whose analytical methods have already been validated using HPLC-grade acetonitrile.  
Chart 1. Ultraviolet Absorbance (1.00 cm cell vs. water)

                                                                                                           
All material in inventory is purified to HPLC standards at our affiliate domestic manufacturing site in the southeastern United States.   An inventory of 1000 liters is typically maintained, allowing for typically short lead times.  Should a requirement for this solvent exist, please contact RCI via Christopher Kulp, Director - Contract Services Business, at 215-628-2946, ext. 13, to inquire about HPLC-grade acetonitrile pricing and availability.

Richman Chemical Inc. now offers new HPAPI Manufacturing Capability

Richman Chemical Inc. (RCI) has tapped its capable network of partners to now offer high potency chemical manufacturing in a cGMP environment to its customers. A high potency active pharmaceutical ingredient (HPAPI) is a drug that carries a higher strength with a smaller amount of actual active pharmaceutical ingredient. Maintaining safety and efficacy while responding to the time sensitive nature inherent to life science firms needing to manufacture these HPAPIs has placed RCI in a pivotal position to respond to this growing requirement.

The HPAPI market segment is expected to grow at a higher rate compared with regular APIs. Most commonly, HPAPIs are produced for use in chemotherapeutic drug formulations. As cancer diagnoses continue to occur at ever-earlier time points, so too has the need to shorten the time-to-market for such therapeutics. There is also increased manufacturing potential for HPAPIs based on research demonstrating the ability of such formulations to treat chronic disease. Since specific manufacturing and containment measures are necessary to produce these high potency APIs, only qualified facilities with knowledge intricate to handling these new chemical entities can manufacture them. RCI's experienced affiliate sites meet all the requisite containment and cGMP requirements for manufacturing such compliant active material.

RCI Newsletter Archive